Summary
Examines how high demand and limited competition have made GLP-1 drugs such as Ozempic and Wegovy prohibitively expensive, compares coverage abroad, and recommends a federal price cap modeled on the insulin cap alongside reforms to pharmacy benefit managers and FDA approvals.
Recommendations
- Implement mandatory federal price caps on GLP-1s based on international pricing standards
- Mandate Medicaid coverage for weight management in states with large food-desert populations
- Require fixed fees instead of rebates or spread pricing for pharmacy benefit managers, and enforce PBM transparency
- Streamline FDA approval of compounded and generic GLP-1 medications
- Extend FDA direct-to-consumer advertising rules to social media and influencer promotion
Keywords
Suggested citation
Economics & Labor Research Team. (2025). Capping the Price of GLP-1s: Quantitative Analysis and Recommendations for Weight Loss Drug Policies in the United States. Harvard Institute of Politics Policy Program. https://harvard-policy.github.io/policy/briefs/capping-glp1-prices.html